RxDoctor Payments Data

Cassidy Pattik, MD

Internal Medicine · South Daytona, FLNPI 1396278719

Payments from drug & device makers

$1,131in general payments, 2019–2025

Across 47 payments — averaging $24.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$410
  • Novo Nordisk$332
  • GSK$114
  • Exact Sciences$56
  • Abbott$49
  • Amgen$37
  • plus $133 from 6 others

What the payments were for

  • Food & beverage$1,131100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,131 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$207,702
Medicare patients
512
Services billed
3,041

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban84$108,507
MounjaroTirzepatide89$96,084
Trelegy ElliptaFluticasone/Umeclidin/Vilanter103$94,084
JardianceEmpagliflozin33$52,469
FarxigaDapagliflozin Propanediol40$45,439
OzempicSemaglutide32$37,069
ProliaDenosumab15$25,843
JanuviaSitagliptin Phosphate18$22,982
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$14,335
Breo ElliptaFluticasone/Vilanterol20$13,973
Spiriva RespimatTiotropium Bromide18$10,119
Atorvastatin Calcium689$6,675
Gabapentin245$5,611
Novolog FlexpenInsulin Aspart24$5,316
Rosuvastatin Calcium389$5,075

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$114$122,392138 claims
PfizerEliquis$410$108,50784 claims
Lilly USA, LLCMounjaro$36$96,08489 claims
Novo NordiskOzempic$332$37,06932 claims
AmgenProlia$37$25,84315 claims
AbbVieSynthroid$14$2,12528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in South Daytona

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →